Acta Biomaterialia, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 1, 2024
Language: Английский
Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)
Published: Feb. 14, 2024
Abstract Despite recent advancements in cancer treatment, this disease still poses a serious threat to public health. Vaccines play an important role preventing illness by preparing the body's adaptive and innate immune responses combat diseases. As our understanding of malignancies their connection system improves, there has been growing interest priming fight more effectively comprehensively. One promising approach involves utilizing nanoparticle systems for antigen delivery, which shown potentiate as vaccines and/or adjuvants. In review, we comprehensively summarized immunological mechanisms while focusing specifically on applications various types nanoparticles field immunotherapy. By exploring these breakthroughs, hope identify significant challenges obstacles making nanoparticle-based adjuvants feasible clinical application. This review serves assess breakthroughs vaccinations shed light prospects potential barriers. doing so, aim inspire future immunotherapies that harness nanotechnology deliver effective targeted treatments. Graphical abstract
Language: Английский
Citations
27
Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)
Published: Feb. 20, 2025
The progression of malignant tumors leads to the development secondary in various organs, including bones, brain, liver, and lungs. This metastatic process severely impacts prognosis patients, significantly affecting their quality life survival rates. Research efforts have consistently focused on intricate mechanisms underlying this corresponding clinical management strategies. Consequently, a comprehensive understanding biological foundations tumor metastasis, identification pivotal signaling pathways, systematic evaluation existing emerging therapeutic strategies are paramount enhancing overall diagnostic treatment capabilities for tumors. However, current research is primarily metastasis within specific cancer types, leaving significant gaps our complex cascade, organ-specific tropism mechanisms, targeted treatments. In study, we examine sequential processes elucidate driving organ-tropic systematically analyze tumors, those tailored organ involvement. Subsequently, synthesize most recent advances technologies challenges opportunities encountered pertaining bone metastasis. Our objective offer insights that can inform future practice crucial field.
Language: Английский
Citations
3
Molecular Biomedicine, Journal Year: 2025, Volume and Issue: 6(1)
Published: Jan. 10, 2025
Abstract Cancer vaccines, crucial in the immunotherapeutic landscape, are bifurcated into preventive and therapeutic types, both integral to combating oncogenesis. Preventive cancer like those against HPV HBV, reduce incidence of virus-associated cancers, while vaccines aim activate dendritic cells cytotoxic T lymphocytes for durable anti-tumor immunity. Recent advancements vaccine platforms, such as synthetic peptides, mRNA, DNA, cellular, nano-vaccines, have enhanced antigen presentation immune activation. Despite US Food Drug Administration approval several full potential remains unrealized due challenges selection, tumor-mediated immunosuppression, optimization delivery systems. This review provides a comprehensive analysis aims implications vaccine, innovative discovery neoantigens enhancing specificity, latest strides platforms. It also critically evaluates role adjuvants immunogenicity mitigating immunosuppressive tumor microenvironment. The further examines synergistic combining with other therapies, chemotherapy, radiotherapy, checkpoint inhibitors, improve outcomes. Overcoming barriers effective identification, microenvironments, adverse effects is critical advancing development. By addressing these challenges, can offer significant improvements patient outcomes broaden scope personalized immunotherapy.
Language: Английский
Citations
2
Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(17)
Published: March 8, 2024
Cancer vaccines provide a potential strategy to cure patients. Their clinical utilization and efficacy is, however, limited by incomplete coverage of tumor neoantigens unspecific restricted activation dendritic cells (DCs). Tumor cell lysates (TCLs) containing broad spectrum neoantigens, while are considered ideal in formulating personalized vaccines, induce generally poor antigen presentation transient antitumor immune response. Here, intelligent polymersomal nanovaccines (PNVs) that quantitatively coload, efficiently codeliver, responsively corelease TCL CpG adjuvant lymph node (LN) DCs developed boost specific robust immunity. PNVs carrying ovalbumin (OVA) markedly enhance the maturation, presentation, downstream T ability bone-marrow-derived strong systemic response after tail base injection. Remarkably, 85% B16-F10 melanoma-bearing mice generate long-lasting anticancer memory at low dose, protecting all cured from rechallenge. These LN-directed being highly versatile straightforward opens new door for cancer vaccines.
Language: Английский
Citations
13
Chemical Society Reviews, Journal Year: 2024, Volume and Issue: 53(15), P. 7657 - 7680
Published: Jan. 1, 2024
Nanomaterials exhibit significant potential for stimulating immune responses, offering both local and systemic modulation across a variety of diseases. The lymphoid organs, such as the spleen lymph nodes, are home to various cells, including monocytes dendritic which contribute progression prevention/treatment Consequently, many nanomaterial formulations being rationally designed target these organs engage with specific cell types, thereby inducing therapeutic protective effects. In this review, we explore crucial cellular interactions processes involved in regulation highlight innovative nano-based immunomodulatory approaches. We outline essential considerations design an emphasis on their impact biological interactions, targeting capabilities, treatment efficacy. Through selected examples, illustrate strategic therapeutically active nanomaterials subsequent immunomodulation infection resistance, inflammation suppression, self-antigen tolerance, cancer immunotherapy. Additionally, address current challenges, discuss emerging topics, share our outlook future developments field.
Language: Английский
Citations
11
Drug Resistance Updates, Journal Year: 2024, Volume and Issue: 75, P. 101098 - 101098
Published: June 1, 2024
Language: Английский
Citations
10
Bioactive Materials, Journal Year: 2024, Volume and Issue: 42, P. 345 - 365
Published: Sept. 6, 2024
Language: Английский
Citations
9
Small Methods, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 28, 2025
Abstract Non‐small cell lung cancer (NSCLC) has a strikingly high incidence rate globally. Although immunotherapy brings great breakthrough in its clinical treatment of NSCLC, significant challenges still need to be overcome. The development novel multi‐functional nanomedicines the realm tumor offers promising opportunities for NSCLC patients, as exhibit advantages, including specific targeting cells, improved drug bioavailability, reduced systemic toxicity, and overcoming immune resistance. In this review, core features current status strategies checkpoint blockade, antibody–drug conjugates, engagers, adoptive vaccines, are surveyed. Particular emphasis is placed on recent that boost these strategies. Nanomedicine can provide perspectives immunotherapy.
Language: Английский
Citations
1
Biomaterials Research, Journal Year: 2024, Volume and Issue: 28
Published: Jan. 1, 2024
Language: Английский
Citations
7
International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 263 - 280
Published: Jan. 1, 2024
Background: Nanovaccines have emerged as a promising vaccination strategy, exhibiting their capacity to deliver antigens and adjuvants elicit specific immune responses. Despite this potential, optimizing the design delivery of nanovaccines remains challenge. Methods: In study, we engineered dendritic mesoporous silica-based nanocarrier enveloped in metal-phenolic network (MPN) layer containing divalent manganese ions tannic acid (MSN@MT). This was tailored for antigen loading serve nanovaccine, aiming activate cyclic GMP-AMP synthase-stimulator interferon genes (cGAS-STING) pathway cells (DCs). Our experimental approach encompassed both cellular assays mouse immunizations, allowing comprehensive evaluation nanovaccine's impact on DC activation its influence generation antigen-specific T-cell Results: MSN@MT demonstrated remarkable enhancement humoral responses mice compared control groups. highlights potential effectively trigger cGAS-STING DCs, resulting robust Conclusion: study introduces MSN@MT, unique incorporating acid, showcasing exceptional ability amplify by activating DCs. innovation signifies stride refining nanovaccine potent activation. Keywords: nanocarrier, network, ions,
Language: Английский
Citations
6